Immunohistochemistry in AML with Recurrent Cytogenetic Abnormalities
AML t(8;21)
|
Usually Positive
|
|
|
HLA_DR
|
Usually Positive (flow marker)
|
|
CD13
|
Usually Positive
|
|
Often Positive
|
|
|
Often Positive
|
|
|
May be Positve (Cytoplasmic)
|
|
|
-/+ (usually weak)
|
|
|
Occasional cases may be positive. Adverse prognostic indicator.
|
AML inv(16) or t(16;16)
|
Usually Positive
|
|
|
Usually Positive
|
|
|
Often positive, but not specific
|
Varying expression of granulocytic and monocytic markers may be seen depending upon differentiation.
APL t(15;17) PML-RARA
|
Weak or negative
|
|
|
HLA_DR
|
Weak or negative (flow marker)
|
|
Often Positive (may be weak)
|
|
|
~20% of cases are positive, associated with a worse prognosis.
|
AML t(9;11) MLLT3-MLL
|
Variably Positive
|
|
|
Variably Positive
|
|
|
Often strong expression
|
AML t(6;9) DEK-NUP214
|
MPO
|
Often Positive
|
|
Usually Positive
|
|
|
Usually Positive
|
|
|
~50% are Positive
|
AML inv(3) or t(3;3) RPN1-EVI1
There is limited data available. Some studies show CD7 may be aberrantly expressed.
AML t(1;22) RBM15-MKL1 (Megakaryoblastic AML)
|
CD41
|
Often Positive
|
|
CD61
|
Often Positive
|
|
CD42
|
Mature platelet marker, which is less often expressed.
|
|
Usually Negative
|
|
|
MPO
|
Usually Negative
|
|
Negative
|
AML with Mutated NPM1
CD34 is usually negative. Myeloid and/or monocytic markers may be positive.
AML with Mutated CEBPA
|
Usually Positive
|
|
|
~50-73% of cases are positive
|
|
|
Usually negative
|
One or more myeloid markers are usually positive.